Question: how long has nuplazid been on the market?
Answer: Nuplazid (pimavanserin) was approved by the U.S. Food and Drug Administration (FDA) in April 2016 under the agency's Breakthrough Therapy Designation, one of four expedited review programs at FDA, applicable to drugs that have shown substantial improvement over existing treatments in early clinical data.